You just read:

FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction

News provided by

Boehringer Ingelheim Pharmaceuticals

Oct 11, 2018, 08:00 ET